Persistent inflammatory response in stroke survivors

Neurology

Volumn 50, Issue 6, 1998, Pages 1722-1728

  Beamer, N B ^a   Coull, Bruce M ^a   Clark, W M ^b,c   Briley, D P ^b   Wynn, M ^b,c   Sexton, G ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; STROKE; SURVIVAL;

EID: 0031780850     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.6.1722     Document Type: Article

References (42)

1. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:39-48.
2. Coull BM, Beamer N, de Garmo P, et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991;22:162-168.
3. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505.
4. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. The Framingham Study: fibrinogen and risk of cardiovascular disease. JAMA 1987;258:1183-1186.
5. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987;317:521-526.
6. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992;117:371-375.
7. Beamer N, Coull BM, Sexton G, de Garmo P, Knox R, Seaman G. Fibrinogen and the albumin-globulin ratio in recurrent stroke. Stroke 1993;24:1133-1139.
8. Beamer NB, Coull BM, Clark WC, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995;37:800-804.
9. Ameriso SF, Wong VLY, Quismorio FP Jr, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke 1991;22:1004-1009.
10. Stuart J, George AJ, Davies AJ, Aukland A, Hurlow RA. Haematological stress syndrome in atherosclerosis. J Clin Pathol 1981;34:464-467.
11. Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen, and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996;82:245-255.
12. Grau AJ, Buggle F, Steichen-Wiehn C, et al. Clinical and biochemical analysis in infection-associated stroke. Stroke 1995;26:1520-1526.
13. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-547.
14. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
15. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
16. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23:1367-1379.
17. Gillum RF, Ingram DD, Makuc DM. White blood cell count and stroke incidence and death: The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1994;139:894-902.
18. Fisher TC, Meiselmann HJ. Polymorphonuclear leukocytes in ischemic vascular disease. Thromb Res 1994;74(suppl 1):s21-s34.
19. Sunyer J, Muñoz A, Peng Y, et al. Longitudinal relation between smoking and white blood cells. Am J Epidemiol 1996; 144:734-741.
20. Yarnell JWG, Sweetnam PW, Rogers S, et al. Some long term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys. J Clin Pathol 1987;40:909-913.
21. Bluethmann H, Rothe J, Schultze N, Tkachuk M, Koebel P. Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukoc Biol 1994;56:565-570.
22. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995;26:1393-1398.
23. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994;122:135-139.
24. Betz AL, Yang G-Y, Davidson BL. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995;15:547-551.
25. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996;16: 932-940.
26. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgärde F, Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996;27:1734-1738.
27. Biffl WL, Moore EE, Moore FA, Barnett CC Jr. Interleukin-6 delays neutrophil apoptosis via a mechanism involving platelet-activating factor. J Trauma Injury Infect Crit Care 1996;40:575-579.
28. Fujishima S, Hoffman AR, Vu T, et al. Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF-α, and IL-1β. J Cell Physiol 1993;154:478-485.
29. Ernst E, Resch KL, Matrai A, Buhl M, Schlosser P, Paulsen HF. Impaired blood rheology: a risk factor after stroke. J Intern Med 1991;229:457-462.
30. Seki Y, Takahashi H, Wada K, Shibata A. Sustained activation of blood coagulation in patients with cerebral thrombosis. Am J Hematol 1995;50:155-160.
31. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke: The Oxfordshire Community Stroke Project. Stroke 1994;25: 333-337.
32. Jennett B, Bond M. Assessment of outcome after brain damage: a practical scale. Lancet 1975;1(7905)480-484.
33. Wityk RJ, Pessin MS, Kaplan RF, Caplan LR. Serial assessment of acute stroke using the NIH Stroke Scale. Stroke 1994; 25:362-365.
34. Adams HPJ, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST, Trial of ORG 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
35. Stata Corporation. STATA, version 5.0. College Station, TX: Stata Corporation, 1996.
36. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-963.
37. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen B8 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler Thromb Vase Biol 1997;17:589-594.
38. Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993;13:1738-1742.
39. Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease: results from the ADEP study. Atherosclerosis 1996;120:25-35.
40. Ohhara N, Okamura S, Kubota A, et al. Levels of serum granulocyte colony-stimulating factor in patients with cerebrovascular diseases. Life Sci 1993;53:939-943.
41. Suzuki S, Kelley RE, Reyes-Iglesias Y, Alfonso VM, Dietrich WD. Cerebrospinal fluid and peripheral white blood cell response to acute cerebral ischemia. South Med J 1995;88:819-824.
42. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996;27:1739-1743.